H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on AzurRx BioPharma Inc (AZRX) today and set a price target of $8. The company’s shares closed yesterday at $1.76, close to its 52-week low of $1.69.
Selvaraju commented:
“Our price target is derived from a discounted cash flow-based asset value of $175M for MS1819, using a 15% discount rate and 2% terminal growth rate, with 50% probability of success. Investment risks include: (1) failure of MS1819 in clinical trials; (2) failure of MS1819 to secure regulatory approval; (3) failure of MS1819 to achieve commercial success due to reimbursement, penetration rate, and/or competition; and (4) dilution risk. AzurRx BioPharma, Inc.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AzurRx BioPharma Inc with a $7 average price target, implying a 297.7% upside from current levels. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $6 price target.
.
See today’s analyst top recommended stocks >>
Based on AzurRx BioPharma Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.57 million. In comparison, last year the company had a GAAP net loss of $3.13 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AzurRx BioPharma, Inc. is a development stage company, which engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It offers MS1819 and AZX1101 that are therapeutic proteins products under development. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
